NLS Pharmaceutics AG: NLS Pharmaceutics Announces $4 Million

ZURICH, SWITZERLAND / ACCESSWIRE / October 3, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and

Related Keywords

Switzerland , Zurich , Züsz , United States , Swiss , Alex Zwyer , Ronald Hafner , George Apostol , Cindy Rizzo , Pascal Nigen , Exchange Commission , Alpha Bronze , Laidlaw Company United Kingdom Ltd , European Medicines Agency , Nasdaq , Pharmaceutics Ltd , Chief Medical Officer , United Kingdom , Securities Act , Orphan Disease Designation , Mazindol Controlled Release , Orphan Drug Designations , Pharmaceutics , Nnounces , Billion , Private , Placement , Conversion , Xisting , Short , Term , Votes ,